Who to call at Trevi Therapeutics, Inc., and when
Fundz watches for the moments Trevi Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Trevi Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Trevi Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Trevi Therapeutics, Inc.. With Fundz connected, it knows.
Trevi Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.trevitherapeutics.com2 executive changes at Trevi Therapeutics in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
Trevi Therapeutics appointed David Hastings as Chief Financial Officer, effective January 6, 2026, with a $522,000 base salary, an annual bonus of up to 40%, and a 375,000-share stock option grant. He previously served as CFO of Arbutus Biopharma (2018 to March 2025) and held CFO roles at Incyte and Unilife.
Key Takeaways
Hastings starts as CFO on January 6, 2026, filling the company's principal financial officer role.
His offer letter sets a $522,000 annualized base salary and an annual incentive bonus of up to 40% of base salary.
3 more takeaways
Related Filings (3)
3 more filings from Trevi Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Trevi Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.